IFN-α2 Antibody (EBI-1): sc-65419
- IFN-α2 Antibody (EBI-1) is a mouse monoclonal IgG1 provided at 100 µg/ml
- raised against IFN-α2 of human origin
- recommended for detection of natural and recombinant IFN-α2 of human origin by ELISA; non cross-reactive with IFN-α8, IFN-α21, or IFN-v
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for IFN-α2 Antibody (EBI-1). This work is in progress.
IFN-α2 Antibody (EBI-1) is a mouse monoclonal IgG antibody that detects IFN-α2 in human samples through enzyme-linked immunosorbent assay (ELISA). IFN-α2, a member of the type I interferon family, plays a crucial role in the immune response by modulating immune cell activity and enhancing the antiviral state of neighboring cells. Anti-IFN-α2 antibody (EBI-1) recognizes a protein primarily secreted by virus-infected cells that initiates body′s defense mechanisms against viral infections. IFN-α2′s ability to activate natural killer cells and promote major histocompatibility complex (MHC) molecule expression underscores importance in both innate and adaptive immunity. IFN-α2 has proven valuable in treating various malignancies and autoimmune disorders, highlighting clinical significance. When IFN-α2 binds to type I interferon receptor, a signaling cascade initiates, leading to interferon-stimulated gene expression and amplified immune response. Given these critical functions and therapeutic applications, IFN-α2 continues to be central in immunological research and clinical therapies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IFN-α2 Antibody (EBI-1) References:
- Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity. | Khine, AA. and Lingwood, CA. 2000. J Cell Physiol. 182: 97-108. PMID: 10567921
- Interferon alpha 2-b therapy of HCV and nonBnonC chronic hepatitis. | Gargiulo, M., et al. 1992. Arch Virol Suppl. 4: 304-5. PMID: 1450709
- IFN-alpha5 mediates stronger Tyk2-stat-dependent activation and higher expression of 2',5'-oligoadenylate synthetase than IFN-alpha2 in liver cells. | Larrea, E., et al. 2004. J Interferon Cytokine Res. 24: 497-503. PMID: 15320963
- The combination of IFN-alpha2 and IFN-alpha8 exhibits synergistic antiproliferative activity on renal cell carcinoma (RCC) cell lines through increased binding affinity for IFNAR-2. | Tanimoto, T., et al. 2007. J Interferon Cytokine Res. 27: 517-23. PMID: 17572016
- Interferon-Alpha 2-a and Its Dual Effect in Treating Two Diseases (Hepatitis C and Polycythemia Vera). | Shwaylia, H., et al. 2021. Case Rep Oncol. 14: 851-854. PMID: 34248550
- Pharmacokinetics of recombinant interferon-alpha 2 following intralesional administration in malignant glioma patients. | Maleci, A., et al. 1987. J Interferon Res. 7: 107-9. PMID: 3585078
- Immunological activities of recombinant interferon-alpha 2 and its A fragment. | Attallah, AM., et al. 1987. J Interferon Res. 7: 223-9. PMID: 3611842
- Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay. | Welander, CE., et al. 1985. Int J Cancer. 35: 721-9. PMID: 4008100
- Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha 2 in natural respiratory viral infections. | Hayden, FG., et al. 1985. Antiviral Res. 5: 111-6. PMID: 4015079
- Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. | Ernstoff, MS. and Kirkwood, JM. 1984. Am J Med. 76: 593-6. PMID: 6711573
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IFN-α2 Antibody (EBI-1) | sc-65419 | 100 µg/ml | $316.00 |